Arterial and venous thrombosis and prothrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin Krakow)

• References

• 1 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
• 2 Sharpe CJ, Crowther MA, Webert KE. et al. Cerebral Venous Thrombosis During Pregnancy in the Setting of Type I Antithrombin Deficiency: Case Report and Literature Review. Transfus Med Rev 2011; 25: 61-65.
• 3 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 197-211.
• 4 Picard V, Chen JM, Tardy B. et al. Detection and characterization of large SERPINC1 deletions in type I inherited antithrombin deficiency. Hum Genet 2010; 127: 45-53.
• 5 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 18: 1094.
• 6 Picard V, Nowak-Göttl U, Biron-Andreani C. et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006; 27: 600.
• 7 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idio pathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
• 8 Lisman T, de Groot PG, Meijers JCM. et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 15: 1102-1105.
• 9 Wolf M, Boyer C, Tripodi A. et al. Antithrombin Milano: A new variant with monomeric and dimeric inactive antithrombin III. Blood 1985; 65: 496-500.
• 10 Scott EM, Ariëns RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566.
• 11 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-142.
• 12 Campbell RA, Overmyer KA, Bagnell R. et al. Cellular procoagulant activity dictates clot structure and stability as a function of distance from the cell surface. Arterioscler Thromb Vasc Biol 2008; 28: 2247-2254.
• 13 Fatah K, Silveira A, Tornvall P. et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
• 14 Jochmans K, Lissens W, Vervoort R. et al. Anti-thrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis. Blood 1994; 83: 146-151.
• 15 Kuhle S, Lane DA, Johamanns A. et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 2001; 86: 1007-1011.
• 16 Roldán V, Ordoñez A, Marín F. et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2009; 101: 483-486.